胺碘酮已广泛应用于治疗心绞痛和心律失常,但对其血浆浓度的测定、血浆浓度与药效之间的关系以及它所导致的QT间期延长的意义都还有争论。本文旨在研究胺碘酮的血浆浓度、心肌浓度、用药剂量及其引起的心电图改变之间的关系。方法:病人9例,6例男性,3例女性,平均年龄57岁,均为缺血性心脏病患者并都准备作冠状动脉旁路移植术。8例术前至少12个月,1例术前9个月开始口服胺碘酮作抗心绞痛或抗心律失常治疗,5例剂量为每天200毫克、4例每天400毫克,每周均用5天。所有病人均符合下列标准:(1)未用过可影响QT间期的其它药物;(2)无束支传导阻滞、预激综合征或其它形式QRS波异常;(3)用胺碘酮 Amiodarone is widely used in the treatment of angina pectoris and arrhythmia, but there is still debate about the determination of plasma concentrations, the relationship between plasma concentrations and pharmacodynamics, and the implications for the prolongation of the QT interval. This article aims to study the relationship between plasma concentrations of amiodarone, cardiac muscle concentration, dosage, and the changes caused by electrocardiograms. Methods: Nine patients, six males and three females, mean age 57 years, were all patients with ischemic heart disease and were all prepared for coronary artery bypass grafting. Eight patients had at least 12 months preoperatively and 1 patient had received amiodarone for anti-angina or antiarrhythmic treatment 9 months prior to surgery. Five doses of 200 mg daily, four 400 mg daily, and five weekly . All patients met the following criteria: (1) no other medications that could affect QT interval were used; (2) bundle branch block, WPW syndrome or other forms of QRS wave abnormalities; (3)